ADAR1 Capital Management LLC Acquires 130,725 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

ADAR1 Capital Management LLC lifted its holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 561.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 154,027 shares of the company's stock after acquiring an additional 130,725 shares during the period. ADAR1 Capital Management LLC owned approximately 0.12% of Centessa Pharmaceuticals worth $2,580,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Jane Street Group LLC acquired a new position in shares of Centessa Pharmaceuticals during the 3rd quarter worth approximately $2,834,000. Wellington Management Group LLP acquired a new stake in Centessa Pharmaceuticals during the third quarter worth approximately $1,609,000. State Street Corp bought a new position in Centessa Pharmaceuticals during the 3rd quarter worth $777,000. Franklin Resources Inc. raised its holdings in Centessa Pharmaceuticals by 99.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company's stock valued at $38,360,000 after acquiring an additional 1,145,823 shares in the last quarter. Finally, Lord Abbett & CO. LLC bought a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter valued at $4,305,000. 82.01% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. TD Cowen started coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating for the company. Piper Sandler initiated coverage on Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an "overweight" rating and a $38.00 price objective for the company. Morgan Stanley reaffirmed an "overweight" rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Finally, Guggenheim reissued a "buy" rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $27.71.

Remove Ads

Centessa Pharmaceuticals Stock Up 2.7 %

Centessa Pharmaceuticals stock traded up $0.30 during mid-day trading on Friday, reaching $11.57. The stock had a trading volume of 635,858 shares, compared to its average volume of 595,614. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals plc has a fifty-two week low of $7.75 and a fifty-two week high of $19.09. The stock's 50-day simple moving average is $15.42 and its 200-day simple moving average is $16.11. The firm has a market capitalization of $1.54 billion, a PE ratio of -7.56 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04. On average, sell-side analysts forecast that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 10,000 shares of the company's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $16.34, for a total value of $163,400.00. Following the completion of the sale, the insider now directly owns 134,021 shares of the company's stock, valued at approximately $2,189,903.14. This represents a 6.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider David M. Chao sold 7,000 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $17.17, for a total value of $120,190.00. Following the completion of the transaction, the insider now owns 225,007 shares in the company, valued at $3,863,370.19. The trade was a 3.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 260,168 shares of company stock worth $4,309,568 in the last quarter. 11.59% of the stock is currently owned by corporate insiders.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.